REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
21/04/2025
Voltar para busca
Dado oficial do USPTO
CAELUM BIOSCIENCES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CAELUM BIOSCIENCES
ST13
US500000087982774Classe
42
Pedido
87982774
Registro
6037766
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
51
Atualização mais recente
22/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
12/01/2017
Data de registro
21/04/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/04/2020
Última transação
22/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/01/2017
Primeiro uso no comércio
01/01/2017
Código do desenho
4
Tipo de titular
03
Localização do titular
New York, NY
Examinador
GALBO, AMANDA
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Caelum Biosciences, Inc.
Representantes
Cara M. Kearney AstraZeneca Pharmaceuticals LP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Biochemical research and development; Biological research; Biotechnology research; Chemicalbiochemicalbiological and bacteriological research and analysis; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Medical research services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research services; Scientific research consulting in the field of amyloidosis and diseases where amyloid deposits are present; Scientific research consulting in the field of obesitydiabetesincontinencecardiovascular diseasescentral nervous system diseases and disordersmetabolic disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseasesauto-immune diseasessolid organ transplant rejectionprogressive organ disease and failure; Scientific research consulting in the field of serious and life threatening diseases; Scientific research for medical purposes in the field of amyloidosis and diseases where amyloid deposits are present; Scientific research for medical purposes in the field of obesitydiabetesincontinencecardiovascular diseasescentral nervous system diseases and disordersmetabolic disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseasesauto-immune diseasessolid organ transplant rejectionprogressive organ disease and failure; Scientific research for medical purposes in the field of serious and life threatening diseases; Research in the field of pharmacogenetics; Conducting clinical trials for others in the field of pharmaceuticals; Research services in the field of proteinsantibodiesmicroorganisms and cells; Research and development services in the field of antibody technology; Structural and functional analysis of genomes; DNA screening for scientific research purposes; Biochemical research and analysis; research and development services in the field of immunology
Publicações
Histórico de despachos e eventos da marca no USPTO.
51 publicações encontradas
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
18/03/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/03/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/03/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/03/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/04/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/04/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/10/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
26/10/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/10/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
21/04/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
17/03/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/03/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
26/02/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
26/02/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
26/02/2020
IUAF
USE AMENDMENT FILED
27/01/2020
DRRR
DIVISIONAL REQUEST RECEIVED
27/01/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
27/01/2020
EISU
TEAS STATEMENT OF USE RECEIVED
27/01/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
27/06/2019
EX3G
SOU EXTENSION 3 GRANTED
25/06/2019
EXT3
SOU EXTENSION 3 FILED
25/06/2019
EEXT
SOU TEAS EXTENSION RECEIVED
25/06/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/01/2019
EX2G
SOU EXTENSION 2 GRANTED
07/01/2019
EXT2
SOU EXTENSION 2 FILED
07/01/2019
EEXT
SOU TEAS EXTENSION RECEIVED
07/01/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/07/2018
EX1G
SOU EXTENSION 1 GRANTED
19/07/2018
EXT1
SOU EXTENSION 1 FILED
19/07/2018
EEXT
SOU TEAS EXTENSION RECEIVED
19/07/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
30/01/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/12/2017
PUBO
PUBLISHED FOR OPPOSITION
05/12/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/11/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/10/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/10/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/10/2017
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
28/04/2017
ALIE
ASSIGNED TO LIE
28/04/2017
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
28/04/2017
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
28/04/2017
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
28/04/2017
DOCK
ASSIGNED TO EXAMINER
06/04/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/01/2017
NWAP
NEW APPLICATION ENTERED
16/01/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CAELUM BIOSCIENCES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.